Shenzhen Hepalink Pharmaceutical, the Shenzhen-listed main business of China billionaire couple Li Li and Li Tan, will invest $60 million in TPG Biotechnology Partners V, which mainly targets biomedical technology and life science companies, Hepalink said today.
In a continued stream of North American deal-making, China's Shenzhen Hepalink Pharmaceutical bought U.S.-based biologics contract manufacturer Cytovance Biologics for $205.7 million and unspecified contingency payments with plans to accelerate the target's expansion plans.
Shenzhen Hepalink buys in to develop Resverlogix cardio candidate in China